Cargando…

Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery

To examine preoperative use of intravitreal dexamethasone implant in patients with refractory diabetic macular edema (DME) undergoing cataract surgery. Participants in this study were 17 patients with DME refractory to previous treatment with anti-vascular endothelial growth factor agents or dexamet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabanarou, Stamatina A., Xirou, Tina, Boutouri, Eirini, Gkizis, Ilias, Vasilias, Dimitrios, Bontzos, Georgios, Chatziralli, Irini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099086/
https://www.ncbi.nlm.nih.gov/pubmed/32218471
http://dx.doi.org/10.1038/s41598-020-62561-3
_version_ 1783511291497807872
author Kabanarou, Stamatina A.
Xirou, Tina
Boutouri, Eirini
Gkizis, Ilias
Vasilias, Dimitrios
Bontzos, Georgios
Chatziralli, Irini
author_facet Kabanarou, Stamatina A.
Xirou, Tina
Boutouri, Eirini
Gkizis, Ilias
Vasilias, Dimitrios
Bontzos, Georgios
Chatziralli, Irini
author_sort Kabanarou, Stamatina A.
collection PubMed
description To examine preoperative use of intravitreal dexamethasone implant in patients with refractory diabetic macular edema (DME) undergoing cataract surgery. Participants in this study were 17 patients with DME refractory to previous treatment with anti-vascular endothelial growth factor agents or dexamethasone implant, and co-existent cataract. All participants received intravitreal dexamethasone implant at baseline and underwent phacoemulsification within one month after its insertion. Best-corrected visual acuity (BCVA) and central subfield thickness (CST) changes between baseline, time of cataract surgery and postoperative months 1, 2 and 3 were evaluated. At month 1 after surgery, BCVA improved significantly from 42.3 ± 9.6 to 58.7 ± 11.9 letters compared to baseline (p < 0.001) and the improvement was sustained at month 2 and month 3 postoperatively. One month postoperatively, CST improved significantly compared to baseline (p < 0.001) and the improvement was sustained at month 2 (p < 0.001), while at month 3 CST started to increase, but remained significantly lower than baseline (p = 0.003). At month 3 postoperatively, 35.3% of patients presented recurrence of ME. Patients with refractory DME and cataract can safely undergo phacoemulsification when dexamethasone implant is inserted one month prior to surgery to ensure adequate control of postoperative inflammation and prevent deterioration of ME.
format Online
Article
Text
id pubmed-7099086
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70990862020-03-31 Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery Kabanarou, Stamatina A. Xirou, Tina Boutouri, Eirini Gkizis, Ilias Vasilias, Dimitrios Bontzos, Georgios Chatziralli, Irini Sci Rep Article To examine preoperative use of intravitreal dexamethasone implant in patients with refractory diabetic macular edema (DME) undergoing cataract surgery. Participants in this study were 17 patients with DME refractory to previous treatment with anti-vascular endothelial growth factor agents or dexamethasone implant, and co-existent cataract. All participants received intravitreal dexamethasone implant at baseline and underwent phacoemulsification within one month after its insertion. Best-corrected visual acuity (BCVA) and central subfield thickness (CST) changes between baseline, time of cataract surgery and postoperative months 1, 2 and 3 were evaluated. At month 1 after surgery, BCVA improved significantly from 42.3 ± 9.6 to 58.7 ± 11.9 letters compared to baseline (p < 0.001) and the improvement was sustained at month 2 and month 3 postoperatively. One month postoperatively, CST improved significantly compared to baseline (p < 0.001) and the improvement was sustained at month 2 (p < 0.001), while at month 3 CST started to increase, but remained significantly lower than baseline (p = 0.003). At month 3 postoperatively, 35.3% of patients presented recurrence of ME. Patients with refractory DME and cataract can safely undergo phacoemulsification when dexamethasone implant is inserted one month prior to surgery to ensure adequate control of postoperative inflammation and prevent deterioration of ME. Nature Publishing Group UK 2020-03-26 /pmc/articles/PMC7099086/ /pubmed/32218471 http://dx.doi.org/10.1038/s41598-020-62561-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kabanarou, Stamatina A.
Xirou, Tina
Boutouri, Eirini
Gkizis, Ilias
Vasilias, Dimitrios
Bontzos, Georgios
Chatziralli, Irini
Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title_full Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title_fullStr Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title_full_unstemmed Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title_short Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
title_sort pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099086/
https://www.ncbi.nlm.nih.gov/pubmed/32218471
http://dx.doi.org/10.1038/s41598-020-62561-3
work_keys_str_mv AT kabanaroustamatinaa preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT xiroutina preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT boutourieirini preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT gkizisilias preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT vasiliasdimitrios preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT bontzosgeorgios preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery
AT chatziralliirini preoperativeintravitrealdexamethasoneimplantinpatientswithrefractorydiabeticmacularedemaundergoingcataractsurgery